Jump to main content
Jump to site search

Issue 5, 2017
Previous Article Next Article

Mapping neuroreceptors with metal-labeled radiopharmaceuticals

Author affiliations

Abstract

The growing epidemiological and economic burden of neurological diseases on society is tremendous. A correct and timely diagnosis can help in lowering the burden and improving the life quality of both the diseased person and the caretaker. Imaging of the brain (neuroimaging) using CT, MRI, and nuclear imaging methods can provide anatomical and functional information. Neuroreceptors are central to neurotransmission and neuromodulation in the CNS. In vivo imaging of receptors in the brain provides powerful tools for the functional study of the central nervous system (CNS) in normal or diseased states. Presently, PET imaging using non-metallic radiotracers dominates the imaging of neuroreceptors. Metal-based probes for SPECT and PET can be economical and logistically easier to use without compromising the information. This review focuses on the development of metallic radiotracers for (99mTc) SPECT and (68Ga) PET along with future directions based on the metallic probes developed for other imaging modalities namely MRI.

Graphical abstract: Mapping neuroreceptors with metal-labeled radiopharmaceuticals

Back to tab navigation

Publication details

The article was received on 04 Nov 2016, accepted on 07 Feb 2017 and first published on 10 Mar 2017


Article type: Review Article
DOI: 10.1039/C6MD00610H
Citation: Med. Chem. Commun., 2017,8, 855-870
  •   Request permissions

    Mapping neuroreceptors with metal-labeled radiopharmaceuticals

    S. Chaturvedi, A. Kaul, P. P. Hazari and A. K. Mishra, Med. Chem. Commun., 2017, 8, 855
    DOI: 10.1039/C6MD00610H

Search articles by author

Spotlight

Advertisements